373 related articles for article (PubMed ID: 16643898)
1. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
Chen PW; Uno T; Ksander BR
Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
[TBL] [Abstract][Full Text] [Related]
2. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
3. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
Wenkel H; Chen PW; Ksander BR; Streilein JW
Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
[TBL] [Abstract][Full Text] [Related]
4. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
[TBL] [Abstract][Full Text] [Related]
5. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner.
Dace DS; Chen PW; Alizadeh H; Niederkorn JY
J Leukoc Biol; 2007 Feb; 81(2):421-9. PubMed ID: 17077163
[TBL] [Abstract][Full Text] [Related]
6. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
Streilein JW; Niederkorn JY
J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1 abrogates anterior chamber-associated immune deviation.
Benson JL; Niederkorn JY
Invest Ophthalmol Vis Sci; 1990 Oct; 31(10):2123-8. PubMed ID: 1698740
[TBL] [Abstract][Full Text] [Related]
9. Immune privilege extended to allogeneic tumor cells in the vitreous cavity.
Jiang LQ; Streilein JW
Invest Ophthalmol Vis Sci; 1991 Jan; 32(1):224-8. PubMed ID: 1987103
[TBL] [Abstract][Full Text] [Related]
10. Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
Ksander BR; Bando Y; Acevedo J; Streilein JW
Cancer Res; 1991 Jun; 51(12):3153-8. PubMed ID: 1904003
[TBL] [Abstract][Full Text] [Related]
11. Analysis of immune deviation elicited by antigens injected into the subretinal space.
Wenkel H; Streilein JW
Invest Ophthalmol Vis Sci; 1998 Sep; 39(10):1823-34. PubMed ID: 9727405
[TBL] [Abstract][Full Text] [Related]
12. Successful immunotherapy of an intraocular tumor in mice.
Schurmans LR; den Boer AT; Diehl L; van der Voort EI; Kast WM; Melief CJ; Toes RE; Jager MJ
Cancer Res; 1999 Oct; 59(20):5250-4. PubMed ID: 10537305
[TBL] [Abstract][Full Text] [Related]
13. Promotion of syngeneic intraocular tumor growth in mice by anterior chamber-associated immune deviation.
Niederkorn JY; Streilein JW; Kripke ML
J Natl Cancer Inst; 1983 Jul; 71(1):193-9. PubMed ID: 6575203
[TBL] [Abstract][Full Text] [Related]
14. Lymphoma allografts abrogate immune privilege within the anterior chamber of the eye.
Niederkorn JY; Streilein JW
Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1235-43. PubMed ID: 3089965
[TBL] [Abstract][Full Text] [Related]
15. Induction of anterior chamber-associated immune deviation (ACAID) by allogeneic intraocular tumors does not require splenic metastases.
Niederkorn JY; Streilein JW
J Immunol; 1982 Jun; 128(6):2470-4. PubMed ID: 6804562
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous immune rejection of intraocular tumors in mice.
Niederkorn JY; Meunier PC
Invest Ophthalmol Vis Sci; 1985 Jun; 26(6):877-84. PubMed ID: 3924853
[TBL] [Abstract][Full Text] [Related]
17. Histopathologic analysis of intraocular allogeneic tumors in mice.
Luckenbach MW; Streilein JW; Niederkorn JY
Invest Ophthalmol Vis Sci; 1985 Oct; 26(10):1368-76. PubMed ID: 3930419
[TBL] [Abstract][Full Text] [Related]
18. Complete elimination ('cure') of progressively growing intraocular tumors by local injection of tumor-specific CD8+ T lymphocytes.
Miki S; Ksander B; Streilein JW
Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3622-34. PubMed ID: 8258521
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of immunity to intraocular tumors in mice.
Niederkorn JY; Streilein JW
Invest Ophthalmol Vis Sci; 1984 Mar; 25(3):336-42. PubMed ID: 6421767
[TBL] [Abstract][Full Text] [Related]
20. Immune privilege to MHC-disparate tumor grafts in the anterior chamber of the eye. I. Quantitative analysis of intraocular tumor growth and the corresponding delayed hypersensitivity response.
Ksander BR; Streilein JW
Transplantation; 1989 Apr; 47(4):661-7. PubMed ID: 2523103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
